Efficacy and safety of sintilimab combined with gemcitabine hydrochloride plus cisplatin in the treatment of advanced lung squamous cell carcinoma
10.3969/j.issn.1009-0754.2025.11.012
- VernacularTitle:信迪利单抗联合盐酸吉西他滨+顺铂治疗晚期肺鳞状细胞癌患者的疗效评价及安全性分析
- Author:
Jiwen YANG
1
;
Yuan XING
Author Information
1. 075000 河北 张家口,河北北方学院附属第一医院药学部静脉用药调配中心
- Keywords:
Squamous cell carcinoma;
Sintilimab;
Gemcitabine hydrochloride;
Cisplatin;
Clinical efficacy
- From:
Journal of Navy Medicine
2025;46(11):1133-1138
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical efficacy and safety of sintilimab combined with gemcitabine hydrochloride plus cisplatin in treating patients with advanced lung squamous cell carcinoma(LSCC).Methods A total of 102 patients with advanced LSCC who were admitted to our hospital between November 2020 and January 2024 were enrolled and randomly assigned to control group(n=51,treated with gemcitabine hydrochloride plus cisplatin)or sintilimab group(n=51,treated with sintilimab,gemcitabine hydrochloride and cisplatin).Clinical efficacy,tumor markers,immune function,quality of life,survival outcomes,and safety were compared between the two groups.Results The objective response rate(ORR)in the sintilimab group was significantly higher than that in the control group(60.78%vs.39.22%,P<0.05).Serum levels of squamous cell carcinoma antigen(SCCAg),carcinoembryonic antigen(CEA),and cytokeratin 19 fragment(CYFRA 21-1)in the sintilimab group were significantly lower than those in the control group after treatment(P<0.05).The sintilimab group had higher CD4+T-cell levels and CD4+/CD8+ratio and lower CD8+T-cell levels than the control group after treatment(P<0.05).The Karnofsky Performance Status(KPS)score was significantly improved in the sintilimab group compared to the control group(P<0.05).Median progression-free survival(PFS)and overall survival(OS)in the sintilimab group were significantly higher than those in the control group(both P<0.05).No significant difference in adverse event rates was observed between the two groups(P>0.05).Conclusion Sintilimab combined with gemcitabine hydrochloride and cisplatin can significantly increase tumor control rates and immune function,prolong survival,improve quality of life,and demonstrate favorable safety in advanced LSCC patients.
